Neurology & Other

The information on this page applies only to the United States 

Our comprehensive portfolio of well-established specialty pharmaceuticals targets neurological diseases such as epilepsy, migraines, depression, chronic pain, Huntington's disease, Parkinson's disease and orphan diseases. Valeant's Neurology and Other product portfolio offers hope for relief to patients suffering from these conditions.

Valeant's key neurology products are Wellbutrin® XL, a once-daily formulation of bupropion for the treatment of depression and seasonal affective disorder and Xenazine® (tetrabenazine),  a medicine that is used to treat the involuntary movements (chorea) of Huntington’s disease and is marketed by Lundbeck.

Potiga™ / Trobalt™

Valeant entered into a strategic partnership with GlaxoSmithKline (GSK) in 2008 for the development and commercialization of the investigational anti-epileptic drug for the adjunctive treatment of adults with partial-onset seizures. Known as Potiga™ in the U.S. and Trobalt™ outside the U.S., we believe Potiga™ / Trobalt™ could offer an important adjunctive treatment option for partial onset seizures that are not well-controlled. On June 13, 2011 Valeant and GSK announced that the U.S. Food and Drug Administration (FDA) approved Potiga™ (ezogabine) Tablets, a potassium channel opener, as adjunctive treatment of partial-onset seizures in patients aged 18 years and older. The FDA has recommended that ezogabine be scheduled as a controlled substance under the Controlled Substances Act (CSA). Final classification is still under review by the Federal Drug Enforcement Administration (DEA) and ezogabine will not be available until this process is complete. Potiga™ was launched in U.S. pharmacies in 2012.

In January 2011, Valeant and GSK were notified that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) had issued a positive opinion, recommending authorization for Trobalt™ as an adjunctive treatment of partial onset seizures and we received final marketing authorization in March 2011. In addition, Trobalt™ received preliminary approval from the Swiss Agency for Therapeutic products, Swissmedic, in December 2010. Trobalt™ launched in May 2011, and is now commercially available in several countries including United Kingdom, Germany, and Switzerland.